Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

CymaBay Therapeutics logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

Advanced Chart

Key Stats

Today's Range
$32.48
$32.48
50-Day Range
$32.18
$32.48
52-Week Range
$7.26
$32.50
Volume
73 shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
CBAY Jul 2024 34.000 call
CBAY Apr 2024 31.000 put
CBAY Oct 2024 33.000 call
See More Headlines

CBAY Stock Analysis - Frequently Asked Questions

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.42 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
2/28/2024
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CBAY
Employees
101
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.37 million
Pretax Margin
-339.11%

Debt

Sales & Book Value

Annual Sales
$31.07 million
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
12.59

Miscellaneous

Free Float
106,693,000
Market Cap
$3.73 billion
Optionable
Optionable
Beta
0.32

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CBAY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners